Clinical-stage
biopharmaceutical company and developers of novel NNR Therapeutics(TM),
Targacept announced that John P. Richard, a Targacept non-executive director
since November 2002, has been appointed as the company’s Chairman of the Board
effective as of January 1, 2014. Richard will continue serving on the company’s
audit and compensation committees.
“John has made countless
contributions to building Targacept since he joined the board in 2002, and we
are grateful that we will continue to benefit from his insight and leadership
in this expanded role,” stated Targacept’s President and Chief Executive
Officer, Dr. Stephen A. Hill. “John’s extensive industry knowledge and business
development experience provides valuable strategic perspective as we build a sustainable
company.”
Richard has substantial
corporate, operational, and transactional life sciences expertise, having
served in a number of executive, director, and advisory positions. Currently
Richard is a partner and director of two life science focused investment firms,
Phase4 Partners and Georgia Venture Partners. John is also a board member of
Biota Pharmaceuticals (NASDAQ: BOTA) and Zosano Pharma, as well as serves as an
advisor to Albireo AB and Nabriva Therapeutics AG. In addition, Richards’s previous
experience includes the role of Executive Vice President, Business Development
at SEQUUS Pharmaceuticals, Inc., where he was responsible for negotiating the
acquisition of SEQUUS by ALZA Corporation. Before joining SEQUUS, John headed
business development for VIVUS, Inc. and Genome Therapeutics Corporation. While
there he was responsible for establishing numerous pharmaceutical alliances. He
was also the CEO and co-founder of Impath Inc., which became part of Genzyme.
Richards earned his M.B.A. from Harvard Business School and his B.S. from
Stanford University.
To learn more, please visit
www.targacept.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
